吸入抗生素在支气管扩张症中的应用现状  

Application status and prospect of inhaled antibiotics in bronchiectasis

作　　者：刘学东[1] 隋风翔[1] 刘菁[1] LIU Xue-dong;SUI Feng-xiang;LIU Jing(Department of Respiratory and Critical Care Medicine,Qingdao Hospital,University of Health and Rehabilitation Sciences(Qingdao Municipal Hospital),Qingdao 266011,Shandong Province,China)

机构地区：[1]康复大学青岛医院、青岛市市立医院呼吸与危重症医学科,山东青岛266011

出　　处：《中国临床药理学杂志》2023年第14期2107-2110,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：支气管扩张症是以支气管异常和持久性扩张为病理特征的慢性呼吸系统疾病。铜绿假单胞菌的感染或定植将严重影响患者预后。我国支气管扩张症疾病患者的负担重,过去一直缺乏有效的药物治疗手段,随着国内吸入抗生素的上市为伴有铜绿假单胞菌感染的支气管扩张症患者提供新的药物选择。本文就目前国内支气管扩张症的临床治疗困境、吸入抗生素在支气管扩张症中的发展和未来方向等进行综述。Bronchiectasis refers to a chronic respiratory disease that are characterized by permanent abnormal dilation of the bronchi.Infection or colonization with Pseudomonas aeruginosa can be associated with a worse prognosis in patients with bronchiectasis.The burden of bronchiectasis in China is very heavy,however there was limited effective drug treatment methods before.The approval of inhaled antibiotics provides new drug choices for Chinese bronchiectasis patients with Pseudomonas aeruginosa infection.In this paper,the current clinical treatment difficulties of bronchiectasis,clinical application and progress of inhaled antibiotics in China were reviewed.

关 键 词：吸入抗生素 支气管扩张症 铜绿假单胞菌 药物选择 

分 类 号：R974[医药卫生—药品]